Clinical Trial Update: ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD [Phase 3]

View source ↗

Summary

This is a Phase 3 pediatric trial (ZIP Study-OL) evaluating safety, pharmacokinetics/pharmacodynamics, efficacy, and immunogenicity of ATB200/AT2221 in children…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pompe Disease

Drugs mentioned

• ATB200/AT2221

Snippet

Sponsor: Amicus Therapeutics | Conditions: Pompe Disease (Late-onset) | Phase 3 | Status: ACTIVE_NOT_RECRUITING